Concepedia

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder, Scott D. Lunin,

The Lancet Haematology · 2021 · 50 citations · 27 references

DOI

Concepts

References

27

Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

Hartmut Döhner, Stephan Stilgenbauer, Axel Benner et al. · New England Journal of Medicine · 2000 · 3.3K citations

, , +17

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text

, , +14

Clinical staging of chronic lymphocytic leukemia

KR Rai, A Sawitsky, Cronkite Ep et al. · Blood · 1975 · 2.7K citations

, , +13

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede, Kirsten Fischer, Raymonde Busch et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

, , +16

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner et al. · The Lancet · 2010 · 1.1K citations

, , +6